ILARIS (canakinumab) for injection is used for the treatment of patients with Periodic Fever Syndromes

ILARIS is an interleukin-1β blocker indicated for the treatment of: 1. Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). 2. Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS). 3. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD). 4. Familial Mediterranean Fever (FMF). Active Systemic Juvenile Idiopathic Arthritis (SJIA).

ILARIS (canakinumab) for injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of ILARIS (canakinumab) for injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ILARIS (canakinumab) for injection medicine cost price in India.

The order for ILARIS (canakinumab) for injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha

ILARIS® (canakinumab) injection, for subcutaneous use Initial U.S. Approval: 2009

Generic Name: canakinumab

For Injection: 150 mg lyophilized powder in single-dose vials for reconstitution.
 Injection: 150 mg/mL solution in single-dose vials.

ILARIS (canakinumab) Injection

GET IN TOUCH
with Indian Pharma Network

Indian Pharma Network, Delhi provides access to ILARIS (canakinumab) on the Named Patient Import basis in India.

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.

BRANCH OFFICE : NEW DELHI | BENGALURU | KOLKATA | LUCKNOW | JODHPUR

Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

ILARIS (canakinumab) for injection suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand ILARIS (canakinumab) for injection on prescription and Import License in Patient's Name only.

For overseas patients, ILARIS (canakinumab) for injection can be made available in Send your enquiry to find ILARIS (canakinumab) for injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for ILARIS (canakinumab) for injection.

For ILARIS (canakinumab) for injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA approves expanded indications for Ilaris for three rare diseases For More Details

Canakinumab (Ilaris) Gets FDA Nod for Three Rare Periodic Fever Syndromes For More Details